About Spyre Therapeutics, Inc.
https://www.spyre.comSpyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
CEO
Cameron Turtle DPHIL,
Compensation Summary
(Year 2023)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-09-08 | Reverse | 1:25 |
ETFs Holding This Stock
Summary
Showing Top 3 of 117
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
FMR LLC
Shares:9.06M
Value:$300.43M
FAIRMOUNT FUNDS MANAGEMENT LLC
Shares:4.02M
Value:$133.24M
BLACKROCK, INC.
Shares:3.98M
Value:$132.07M
Summary
Showing Top 3 of 147
About Spyre Therapeutics, Inc.
https://www.spyre.comSpyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $11.64M ▼ | $-11.18M ▲ | 0% | $-0.15 ▲ | $-11.18M ▲ |
| Q2-2025 | $0 | $41.94M ▼ | $-36.72M ▲ | 0% | $-0.6 ▼ | $-51.94M ▲ |
| Q1-2025 | $0 | $53.57M ▼ | $-44.77M ▲ | 0% | $-0.13 ▲ | $-53.57M ▲ |
| Q4-2024 | $0 | $61.25M ▲ | $-56.3M ▲ | 0% | $-0.15 ▲ | $-61.25M ▼ |
| Q3-2024 | $0 | $55.39M | $-69.03M | 0% | $-1.36 | $-55.39M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $486.2M ▼ | $504.6M ▼ | $49.5M ▼ | $455.1M ▼ |
| Q2-2025 | $526.58M ▼ | $538.83M ▼ | $83.06M ▼ | $455.77M ▼ |
| Q1-2025 | $564.82M ▼ | $569.78M ▼ | $87.17M ▼ | $482.61M ▼ |
| Q4-2024 | $603.09M ▲ | $608.48M ▲ | $90.68M ▼ | $517.8M ▲ |
| Q3-2024 | $414.23M | $421.09M | $93.7M | $327.39M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-11.18M ▲ | $-37.12M ▲ | $25M ▼ | $-4.64M ▼ | $-16.76M ▼ | $-37.12M ▲ |
| Q2-2025 | $-36.72M ▲ | $-46.56M ▼ | $79M ▲ | $731K ▲ | $33.17M ▲ | $-46.56M ▼ |
| Q1-2025 | $-44.77M ▲ | $-40.99M ▼ | $-61K ▲ | $125K ▼ | $-40.93M ▼ | $-40.99M ▼ |
| Q4-2024 | $-56.3M ▲ | $-37.2M ▼ | $-170.54M ▼ | $225.6M ▲ | $17.84M ▼ | $-37.2M ▼ |
| Q3-2024 | $-69.03M | $-29.42M | $42.74M | $12.78M | $26.11M | $-29.42M |
CEO
Cameron Turtle DPHIL,
Compensation Summary
(Year 2023)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-09-08 | Reverse | 1:25 |
ETFs Holding This Stock
Summary
Showing Top 3 of 117
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
FMR LLC
Shares:9.06M
Value:$300.43M
FAIRMOUNT FUNDS MANAGEMENT LLC
Shares:4.02M
Value:$133.24M
BLACKROCK, INC.
Shares:3.98M
Value:$132.07M
Summary
Showing Top 3 of 147